Legend Biotech CFO Resigns Effective Jan 2, 2025
Ticker: LEGN · Form: 6-K · Filed: Dec 23, 2024 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, cfo-resignation
TL;DR
Legend Biotech CFO Lori Macomber is out Jan 2nd, citing personal reasons.
AI Summary
Legend Biotech Corporation announced on December 18, 2024, that its Chief Financial Officer, Lori Macomber, will resign effective January 2, 2025, for personal reasons. She has entered into a Transition Agreement with the company.
Why It Matters
A change in a key executive position like CFO can impact investor confidence and the company's financial strategy.
Risk Assessment
Risk Level: medium — A CFO resignation can signal underlying issues or create uncertainty regarding financial leadership and strategy.
Key Players & Entities
- Legend Biotech Corporation (company) — Registrant
- Lori Macomber (person) — Chief Financial Officer
- January 2, 2025 (date) — Effective Date of resignation
- December 18, 2024 (date) — Date of Transition Agreement
FAQ
What is the effective date of Lori Macomber's resignation as CFO?
Lori Macomber's resignation as Chief Financial Officer of Legend Biotech Corporation is effective as of January 2, 2025.
What is the stated reason for Lori Macomber's resignation?
The stated reason for Lori Macomber's resignation is for personal reasons.
When did Legend Biotech Corporation enter into the Transition Agreement with Lori Macomber?
Legend Biotech Corporation entered into the Transition Agreement with Lori Macomber on December 18, 2024.
What is the company file number for Legend Biotech Corporation?
The commission file number for Legend Biotech Corporation is 001-39307.
What is the principal executive office address for Legend Biotech Corporation?
The principal executive office address for Legend Biotech Corporation is 2101 Cottontail Lane, Somerset, New Jersey 08873.
Filing Stats: 588 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2024-12-23 16:01:34
Filing Documents
- f6k_122324.htm (6-K) — 12KB
- exh_991.htm (EX-99.1) — 91KB
- exh991_01.jpg (GRAPHIC) — 199KB
- exh991_02.jpg (GRAPHIC) — 260KB
- exh991_03.jpg (GRAPHIC) — 264KB
- exh991_04.jpg (GRAPHIC) — 281KB
- exh991_05.jpg (GRAPHIC) — 288KB
- exh991_06.jpg (GRAPHIC) — 250KB
- exh991_07.jpg (GRAPHIC) — 287KB
- exh991_08.jpg (GRAPHIC) — 289KB
- exh991_09.jpg (GRAPHIC) — 291KB
- exh991_10.jpg (GRAPHIC) — 89KB
- exh991_11.jpg (GRAPHIC) — 75KB
- exh991_12.jpg (GRAPHIC) — 204KB
- exh991_13.jpg (GRAPHIC) — 54KB
- exh991_14.jpg (GRAPHIC) — 132KB
- exh991_15.jpg (GRAPHIC) — 40KB
- exh991_16.jpg (GRAPHIC) — 288KB
- exh991_17.jpg (GRAPHIC) — 306KB
- exh991_18.jpg (GRAPHIC) — 283KB
- exh991_19.jpg (GRAPHIC) — 293KB
- exh991_20.jpg (GRAPHIC) — 275KB
- exh991_21.jpg (GRAPHIC) — 234KB
- exh991_22.jpg (GRAPHIC) — 118KB
- exh991_23.jpg (GRAPHIC) — 274KB
- exh991_24.jpg (GRAPHIC) — 265KB
- exh991_25.jpg (GRAPHIC) — 203KB
- exh991_26.jpg (GRAPHIC) — 74KB
- exh991_27.jpg (GRAPHIC) — 209KB
- exh991_28.jpg (GRAPHIC) — 196KB
- exh991_29.jpg (GRAPHIC) — 81KB
- 0001171843-24-007063.txt ( ) — 8508KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date: December 23, 2024 By: /s/ Ying Huang Name: Ying Huang, Ph.D. Title: Chief Executive Officer